Celyad Oncology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Celyad Oncology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	34.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Dec 31

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Celyad Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ENXTBR:CYAD - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	0	-8	-10	-10	N/A
3/31/2024	0	-8	-13	-12	N/A
12/31/2023	0	-8	-16	-15	N/A
9/30/2023	0	-20	-18	-18	N/A
6/30/2023	0	-31	-20	-20	N/A
3/31/2023	0	-35	N/A	N/A	N/A
12/31/2022	N/A	-41	-28	-28	N/A
9/30/2022	N/A	-32	N/A	N/A	N/A
6/30/2022	N/A	-26	-31	-31	N/A
3/31/2022	N/A	-25	N/A	N/A	N/A
12/31/2021	N/A	-27	-27	-27	N/A
9/30/2021	N/A	-17	N/A	N/A	N/A
6/30/2021	N/A	-15	-26	-25	N/A
3/31/2021	0	-18	N/A	N/A	N/A
12/31/2020	0	-17	-28	-28	N/A
9/30/2020	0	-28	N/A	N/A	N/A
6/30/2020	0	-29	-27	-27	N/A
3/31/2020	0	-29	-28	-27	N/A
12/31/2019	0	-29	-29	-28	N/A
9/30/2019	0	-32	-30	-29	N/A
6/30/2019	1	-35	-31	-29	N/A
3/31/2019	2	-36	-30	-28	N/A
12/31/2018	3	-37	-29	-27	N/A
9/30/2018	3	-49	N/A	N/A	N/A
6/30/2018	3	-60	-45	-44	N/A
3/31/2018	3	-58	N/A	-44	N/A
12/31/2017	4	-56	N/A	-44	N/A
9/30/2017	9	-39	N/A	N/A	N/A
6/30/2017	12	-21	N/A	-18	N/A
3/31/2017	10	-22	N/A	-22	N/A
12/31/2016	10	-24	N/A	-25	N/A
9/30/2016	4	-27	N/A	-31	N/A
6/30/2016	0	-31	N/A	-38	N/A
3/31/2016	0	-30	N/A	-32	N/A
12/31/2015	0	-29	N/A	-27	N/A
9/30/2015	0	-27	N/A	-24	N/A
6/30/2015	0	-25	N/A	-21	N/A
3/31/2015	0	-21	N/A	-19	N/A
12/31/2014	0	-16	N/A	-17	N/A
9/30/2014	0	-15	N/A	-15	N/A
6/30/2014	N/A	-14	N/A	-13	N/A
3/31/2014	N/A	-15	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CYAD's forecast earnings growth is above the savings rate (1.3%).

Earnings vs Market: Insufficient data to determine if CYAD's earnings are forecast to grow faster than the Belgian market

High Growth Earnings: Insufficient data to determine if CYAD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CYAD's revenue is forecast to grow faster than the Belgian market.

High Growth Revenue: Insufficient data to determine if CYAD's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CYAD's Return on Equity is forecast to be high in 3 years time

Celyad Oncology Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus forecasts updated

Forecast to breakeven in 2023

Price target decreased to €14.75

Analysts update estimates

Recent updates

Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024

Celyad Oncology SA to Report First Half, 2025 Results on Sep 25, 2025

Celyad Oncology SA to Report First Half, 2024 Results on Sep 20, 2024

Celyad Oncology SA to Report First Half, 2024 Results on Aug 06, 2024

Celyad Oncology Sa Announces Executive Change

Celyad Oncology SA announced that it has received €9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.

Celyad Oncology SA ADR - Sponsored to Be Deleted from OTC Equity

Celyad Oncology SA, Annual General Meeting, May 06, 2024

Celyad Oncology SA to Report First Half, 2023 Results on Sep 04, 2023

Celyad Oncology SA announced that it expects to receive €9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors

Nasdaq to Delist the American Depositary Shares of Celyad Oncology

Celyad Oncology Receives Notification Letter from Nasdaq Regarding ADS's Scheduled for Delisting from The Nasdaq Global Market and to be Suspended at the Opening of U.S. Business on May 19, 2023

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares from Nasdaq

Celyad Oncology Announces Publication of Data from Its Phase 1 Think Study of CYAD-01

Celyad Oncology SA to Report Q1, 2023 Results on May 05, 2023

Celyad Oncology SA to Report Q3, 2023 Results on Nov 09, 2023

Less than half of directors are independent

Celyad Oncology Provides Update on Clinical Trial Programs

Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for €6 million.

Celyad Oncology Sa Announces Fda Lifts Clinical Hold of Cyad-101-002 Phase 1B Trial

Celyad Oncology SA Announces Chief Financial Officer Changes

Celyad Oncology SA Announces Board Changes

Less than half of directors are independent

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology SA Announces Voluntary Pause of CYAD-101-002 Phase 1B Trial

Celyad Oncology SA Announces Program Update and Anticipated Milestones for 2022

Celyad Oncology SA Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

Consensus forecasts updated

Celyad Oncology SA Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition

Celyad Oncology SA announced that it expects to receive €28.73 million in funding from Fortress Investment Group LLC

Forecast to breakeven in 2023

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Price target decreased to €14.75

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma At the European Hematology Association Virtual Congress

Full year 2020 earnings released: €1.23 loss per share (vs €2.29 loss in FY 2019)

Celyad Oncology SA to Report Fiscal Year 2020 Results on Mar 24, 2021

New 90-day low: €6.42

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

Celyad Oncology SA Appoints Marina Udier, Ph.D., to Board of Directors

Celyad Oncology SA announced that it expects to receive $40 million in funding from Lincoln Park Capital, LLC

We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Analysts update estimates

Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC

Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma

New 90-day low: €7.64

Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

New 90-day low: €8.13

New 90-day low - €8.34

Earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies